{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:10:28Z","timestamp":1793146228641,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>While the role of drug-eluting beads transarterial chemoembolization (DEB-TACE) for hepatocellular carcinoma (HCC) is established, questions regarding appropriate bead size for use in patients remain. This trial evaluated the effectiveness and safety of DEB-TACE using small-size (\u2264\u2009100\u00a0\u03bcm) microspheres loaded with epirubicin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and Methods<\/jats:title>\n                <jats:p>This prospective, single-arm, multicenter study enrolled patients diagnosed with HCC who underwent DEB-TACE using 40 (range, 30\u201350), 75 (range, 60\u201390), or 100 (range, 75\u2013125) \u03bcm epirubicin-loaded microspheres (TANDEM microspheres, Varian Medical). Bead size was at the discretion of treating physicians and based on tumor size and\/or vascular structure. The primary outcome measure was 6-month objective response rate (ORR). Secondary outcome measures were 30-day and 3-month ORR, time to tumor progression and extrahepatic spread, proportion of progression-free survival and overall survival (OS) at one year, and incidence of treatment-associated adverse events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Data from 108 patients from ten centers was analyzed. Six-month ORR was 73.3 and 71.3% based on European association for the study of the liver (EASL) and modified response evaluation criteria in solid tumors (mRECIST) criteria, respectively. Thirty-day ORR was 79.6% for both EASL and mRECIST criteria with 3-month ORR being 80.0 and 81.0%, respectively, for each criteria. One-year PPF and OS rate were 60.3 and 94.3%. There was a total of 30 SAEs reported to be likely to definitely associated with microsphere (<jats:italic>n<\/jats:italic>\u2009=\u20099), epirubicin (<jats:italic>n<\/jats:italic>\u2009=\u20099), or procedure (<jats:italic>n<\/jats:italic>\u2009=\u200912) with none resulting in death.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>DEB-TACE using epirubicin-loaded small-sized (\u2264\u2009100\u00a0\u03bcm) microspheres demonstrates promising local tumor control and acceptable safety in patients with HCC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial Registration<\/jats:title>\n                <jats:p>Clinicaltrials.gov NCT03113955; registered April 14, 2017.<\/jats:p>\n                <jats:p><jats:italic>Trial Registration<\/jats:italic> Clinicaltrials.gov NCT03113955; registered April 14, 2017.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Level of evidence<\/jats:title>\n                <jats:p>2, Prospective, Non-randomized, Single-arm, study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00270-024-03666-4","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T18:02:18Z","timestamp":1709056938000},"page":"325-336","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Transarterial Chemoembolization with Epirubicin-Loaded Microspheres for Hepatocellular Carcinoma: A Prospective, Single-Arm, Multicenter, Phase 2 Study (STOPPER Trial)"],"prefix":"10.1007","volume":"47","clinical-trial-number":[{"clinical-trial-number":"nct03113955","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Hai-Dong","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Hui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ping","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Liang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Feng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Gong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin-Yan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1145-0798","authenticated-orcid":false,"given":"Gao-Jun","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"key":"3666_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018","author":"M Reig","year":"2021","unstructured":"Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation barcelona clinic liver cancer (BCLC) staging system. J Hepatol. 2021. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018.","journal-title":"J Hepatol"},{"key":"3666_CR2","doi-asserted-by":"publisher","first-page":"661","DOI":"10.21037\/hbsn-21-260","volume":"10","author":"J Lu","year":"2021","unstructured":"Lu J, Zhao M, Arai Y, et al. Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of international society of multidisciplinary interventional oncology (ISMIO). Hepatobiliary Surg Nutr. 2021;10:661\u201371.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"3666_CR3","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1111\/liv.12818","volume":"35","author":"JW Park","year":"2015","unstructured":"Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int. 2015;35:2155\u201366.","journal-title":"Liver Int"},{"key":"3666_CR4","doi-asserted-by":"publisher","first-page":"e183213","DOI":"10.1001\/jamanetworkopen.2018.3213","volume":"1","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Zhang M, Chen M, et al. Association of sustained response duration with survival after conventional transarterial chemoembolization in patients with hepatocellular carcinoma. JAMA Netw Open. 2018;1:e183213.","journal-title":"JAMA Netw Open"},{"key":"3666_CR5","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734\u20139.","journal-title":"Lancet"},{"key":"3666_CR6","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"CM Lo","year":"2002","unstructured":"Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164\u201371.","journal-title":"Hepatology"},{"key":"3666_CR7","doi-asserted-by":"publisher","first-page":"808","DOI":"10.4254\/wjh.v9.i18.808","volume":"9","author":"JE Song","year":"2017","unstructured":"Song JE, Kim DY. Conventional versus drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma. World J Hepatol. 2017;9:808\u201314.","journal-title":"World J Hepatol"},{"key":"3666_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/hep.28453","volume":"64","author":"R Lencioni","year":"2016","unstructured":"Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016;64:106\u201316.","journal-title":"Hepatology"},{"key":"3666_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3748\/wjg.v24.i2.161","volume":"24","author":"A Facciorusso","year":"2018","unstructured":"Facciorusso A. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: current state of the art. World J Gastroenterol. 2018;24:161\u20139.","journal-title":"World J Gastroenterol"},{"key":"3666_CR10","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00330-016-4488-y","volume":"27","author":"A Monier","year":"2017","unstructured":"Monier A, Guiu B, Duran R, et al. Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion. Eur Radiol. 2017;27:1431\u20139.","journal-title":"Eur Radiol"},{"key":"3666_CR11","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.rx.2015.01.008","volume":"57","author":"JE Meg\u00edas Vericat","year":"2015","unstructured":"Meg\u00edas Vericat JE, Garc\u00eda Marcos R, L\u00f3pez Briz E, et al. Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: a study of effectiveness, safety and costs. Radiologia. 2015;57:496\u2013504.","journal-title":"Radiologia"},{"issue":"24","key":"3666_CR12","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.3390\/cancers13246172","volume":"13","author":"KI Bzeizi","year":"2021","unstructured":"Bzeizi KI, Arabi M, Jamshidi N, et al. Conventional transarterial chemoembolization versus drug-eluting beads in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Cancers (Basel). 2021;13(24):6172.","journal-title":"Cancers (Basel)"},{"key":"3666_CR13","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2147\/JHC.S319920","volume":"8","author":"WC Chang","year":"2021","unstructured":"Chang WC, Hsu HH, Chiu SH, et al. Transcatheter arterial chemoembolization with drug-eluting beads for the treatment of hepatocellular carcinoma: recommended selection for small-caliber (<100 mum) Beads. J Hepatocell Carcinoma. 2021;8:937\u201349.","journal-title":"J Hepatocell Carcinoma"},{"key":"3666_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13660","author":"J Zhang","year":"2021","unstructured":"Zhang J, Feng GA, Li Y, Wang W. Drug-eluting bead transarterial chemoembolization with medium-sized versus small-sized CalliSpheres microspheres in unresectable primary liver cancer. Asia Pac J Clin Oncol. 2021. https:\/\/doi.org\/10.1111\/ajco.13660.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"2","key":"3666_CR15","first-page":"297","volume":"12","author":"JW Yi","year":"2022","unstructured":"Yi JW, Hong HP, Kim MS, et al. Comparison of clinical efficacy and safety between 70\u2013150\u00a0microm and 100\u2013300\u00a0microm doxorubicin drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma. Life (Basel). 2022;12(2):297.","journal-title":"Life (Basel)"},{"key":"3666_CR16","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.2217\/fon-2018-0237","volume":"14","author":"J Delicque","year":"2018","unstructured":"Delicque J, Guiu B, Boulin M, Schwanz H, Piron L, Cassinotto C. Liver chemoembolization of hepatocellular carcinoma using TANDEM(R) microspheres. Future Oncol. 2018;14:2761\u201372.","journal-title":"Future Oncol"},{"key":"3666_CR17","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jvir.2014.04.005","volume":"25","author":"T Tanaka","year":"2014","unstructured":"Tanaka T, Nishiofuku H, Hukuoka Y, et al. Pharmacokinetics and antitumor efficacy of chemoembolization using 40\u00a0\u00b5m irinotecan-loaded microspheres in a rabbit liver tumor model. J Vasc Interv Radiol. 2014;25:1037-1044.e1032.","journal-title":"J Vasc Interv Radiol"},{"key":"3666_CR18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s13318-022-00762-z","volume":"47","author":"M Zarisfi","year":"2022","unstructured":"Zarisfi M, Kasaeian A, Wen A, Liapi E. Systematic review and pharmacokinetic meta-analysis of doxorubicin exposure in transcatheter arterial chemoembolization and doxorubicin-eluted beads chemoembolization for treatment of unresectable hepatocellular carcinoma. Eur J Drug Metab Pharmacokinet. 2022;47:449\u201366.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"3666_CR19","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.jvir.2014.12.016","volume":"26","author":"DM Gnutzmann","year":"2015","unstructured":"Gnutzmann DM, Mechel J, Schmitz A, et al. Evaluation of the plasmatic and parenchymal elution kinetics of two different irinotecan-loaded drug-eluting embolics in a pig model. J Vasc Interv Radiol. 2015;26:746\u201354.","journal-title":"J Vasc Interv Radiol"},{"key":"3666_CR20","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jvir.2014.08.021","volume":"26","author":"B Guiu","year":"2015","unstructured":"Guiu B, Schmitt A, Reinhardt S, et al. Idarubicin-loaded ONCOZENE drug-eluting embolic agents for chemoembolization of hepatocellular carcinoma: in vitro loading and release and in vivo pharmacokinetics. J Vasc Interv Radiol. 2015;26:262\u201370.","journal-title":"J Vasc Interv Radiol"},{"key":"3666_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00270-015-1154-8","volume":"39","author":"HL She","year":"2016","unstructured":"She HL, Burgmans MC, Coenraadm M, Saraqueta AF. In vivo proof of superselective transarterial chemoembolization with 40\u00a0\u03bcm drug-eluting beads in a patient with hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2016;39:137\u201340.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3666_CR22","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4329\/wjr.v9.i5.245","volume":"9","author":"G Greco","year":"2017","unstructured":"Greco G, Cascella T, Facciorusso A, et al. Transarterial chemoembolization using 40\u00a0\u00b5m drug eluting beads for hepatocellular carcinoma. World J Radiol. 2017;9:245\u201352.","journal-title":"World J Radiol"},{"key":"3666_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5334\/jbsr.1841","volume":"103","author":"H Balli","year":"2019","unstructured":"Balli H, Aksungur E, Khalatai B, Aikimbaev K. Super-selective transarterial chemoembolization with doxorubicin-loaded drug-eluting beads sized below and above 100 microns in hepatocellular carcinoma: a comparative study. J Belg Soc Radiol. 2019;103:47.","journal-title":"J Belg Soc Radiol"},{"key":"3666_CR24","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s00270-016-1382-6","volume":"39","author":"K Malagari","year":"2016","unstructured":"Malagari K, Kiakidis T, Pomoni M, et al. Pharmacokinetics, safety, and efficacy of chemoembolization with doxorubicin-loaded tightly calibrated small microspheres in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2016;39:1379\u201391.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3666_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.21037\/tcr.2019.01.36","volume":"8","author":"GH Zhou","year":"2019","unstructured":"Zhou GH, Sun JH, Zhang YL, et al. Transcatheter embolization of hepatocellular carcinoma with epirubicin-loaded DC beads in Chinese patients. Transl Cancer Res. 2019;8:279\u201389.","journal-title":"Transl Cancer Res"},{"key":"3666_CR26","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1186\/s12885-018-4566-4","volume":"18","author":"GH Zhou","year":"2018","unstructured":"Zhou GH, Han J, Sun JH, et al. Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres\u00ae beads in Chinese hepatocellular carcinoma patients. BMC Cancer. 2018;18:644.","journal-title":"BMC Cancer"},{"key":"3666_CR27","first-page":"1025","volume":"38","author":"T Sattler","year":"2018","unstructured":"Sattler T, Bredt C, Surwald S, Rust C, Rieger J, Jakobs T. Efficacy and safety of drug eluting bead tace with microspheres <150\u00a0mum for the treatment of hepatocellular carcinoma. Anticancer Res. 2018;38:1025\u201332.","journal-title":"Anticancer Res"},{"key":"3666_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1159\/000488035","volume":"7","author":"J Zhou","year":"2018","unstructured":"Zhou J, Sun HC, Wang Z, et al. Guidelines for diagnosis and treatment of primary liver cancer in China. Liv Cancer. 2018;7:235\u201360.","journal-title":"Liv Cancer."},{"key":"3666_CR29","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1093\/annonc\/mdt247","volume":"24","author":"L Kadalayil","year":"2013","unstructured":"Kadalayil L, Benini R, Pallan L, et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol. 2013;24:2565\u201370.","journal-title":"Ann Oncol"},{"issue":"8","key":"3666_CR30","first-page":"840","volume":"11","author":"GH Kim","year":"2021","unstructured":"Kim GH, Kim JH, Shim JH, et al. Chemoembolization for single large hepatocellular carcinoma with preserved liver function: analysis of factors predicting clinical outcomes in a 302 patient cohort. Life (Basel). 2021;11(8):840.","journal-title":"Life (Basel)"},{"key":"3666_CR31","unstructured":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69:182\u2013236"},{"key":"3666_CR32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52\u201360.","journal-title":"Semin Liver Dis"},{"key":"3666_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","volume":"33","author":"J Lammer","year":"2010","unstructured":"Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41\u201352.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3666_CR34","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00270-014-0907-0","volume":"38","author":"C Spreafico","year":"2015","unstructured":"Spreafico C, Cascella T, Facciorusso A, et al. Transarterial chemoembolization for hepatocellular carcinoma with a new generation of beads: clinical-radiological outcomes and safety profile. Cardiovasc Intervent Radiol. 2015;38:129\u201334.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3666_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00432-020-03370-z","volume":"147","author":"KC Albrecht","year":"2021","unstructured":"Albrecht KC, Aschenbach R, Diamantis I, Eckardt N, Teichgr\u00e4ber U. Response rate and safety in patients with hepatocellular carcinoma treated with transarterial chemoembolization using 40\u00a0\u00b5m doxorubicin-eluting microspheres. J Cancer Res Clin Oncol. 2021;147:23\u201332.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3666_CR36","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s00270-019-02260-3","volume":"42","author":"K Malagari","year":"2019","unstructured":"Malagari K, Moschouris H, Kiakidis T, et al. Five-years outcome analysis of 142 consecutive hepatocellular carcinoma patients treated with doxorubicin eluting microspheres 30\u201360\u00a0\u03bcm: results from a single-centre prospective phase ii trial. Cardiovasc Intervent Radiol. 2019;42:1551\u201362.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3666_CR37","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jvir.2020.06.009","volume":"31","author":"HY Ou","year":"2020","unstructured":"Ou HY, Wu YN, Yu CY, et al. Transarterial chemoembolization using 100\u00a0\u03bcm drug-eluting microspheres in patients with hepatocellular carcinoma: a prospective study and midterm follow-up. J Vasc Interv Radiol. 2020;31:1784\u201391.","journal-title":"J Vasc Interv Radiol"},{"key":"3666_CR38","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00270-017-1839-2","volume":"41","author":"G Richter","year":"2018","unstructured":"Richter G, Radeleff B, Stroszczynski C, et al. Safety and feasibility of chemoembolization with doxorubicin-loaded small calibrated microspheres in patients with hepatocellular carcinoma: results of the MIRACLE I prospective multicenter study. Cardiovasc Intervent Radiol. 2018;41:587\u201393.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3666_CR39","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jhep.2016.01.012","volume":"64","author":"R Lencioni","year":"2016","unstructured":"Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol. 2016;64:1090\u20138.","journal-title":"J Hepatol"},{"key":"3666_CR40","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s00270-012-0352-x","volume":"35","author":"S Sahara","year":"2012","unstructured":"Sahara S, Kawai N, Sato M, et al. Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2012;35:1363\u201371.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3666_CR41","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/liv.12083","volume":"33","author":"JW Park","year":"2013","unstructured":"Park JW, Amarapurkar D, Chao Y, et al. Consensus recommendations and review by an International expert panel on interventions in hepatocellular carcinoma (EPOIHCC). Liver Int. 2013;33:327\u201337.","journal-title":"Liver Int"},{"key":"3666_CR42","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3727\/096504019X15662966719585","volume":"28","author":"J Sun","year":"2020","unstructured":"Sun J, Zhou G, Xie X, et al. Efficacy and safety of drug-eluting beads transarterial chemoembolization by calliSpheres(R) in 275 hepatocellular carcinoma patients: results from the Chinese CalliSpheres(R) transarterial chemoembolization in liver cancer (CTILC) study. Oncol Res. 2020;28:75\u201394.","journal-title":"Oncol Res"},{"issue":"5","key":"3666_CR43","doi-asserted-by":"publisher","first-page":"661","DOI":"10.21037\/hbsn-21-260","volume":"10","author":"J Lu","year":"2021","unstructured":"Lu J, Zhao M, Arai Y, et al. Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of international society of multidisciplinary interventional oncology (ISMIO). Hepatobiliary Surg Nutr. 2021;10(5):661\u201371.","journal-title":"Hepatobiliary Surg Nutr"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-024-03666-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-024-03666-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-024-03666-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T22:02:37Z","timestamp":1710108157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-024-03666-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,27]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["3666"],"URL":"https:\/\/doi.org\/10.1007\/s00270-024-03666-4","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,27]]},"assertion":[{"value":"24 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors have reviewed this manuscript and support its submission. Consent for publication was obtained for every individual person\u2019s data included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}